“Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis (marijuana) products, has introduced 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
Cannabis Science has received images and documented information from this 4th patient who has basal cell carcinoma on his left nostril. The patient is enrolled in a photographic mole-mapping programme at the University of Colorado Hospital and is examined annually. The last time he was examined was in October of 2011, where his doctors found a small bump on his left nostril that was less and 1/8″ in diameter, and believed it to be basal cell carcinoma. At that time it was too early to be certain if it was in-fact basal cell carcinoma.
By January 2012 the small bump on his left nostril had grown slightly and had developed a rough scaly texture similar to his previous episodes of basal cell carcinoma. The patient began self-administering cannabis extract oil (CT-1) topically to the spot on his left nostril in the middle of January. The patient immediately reported minor irritation of the spot but that the surrounding healthy skin was not irritated. The rough scaly texture and the minor irritation disappeared by day four of treatment and by day nine of treatment the bump had shrunk considerably and was almost imperceptible to the touch. In these three images you can notice a significant reduction in the lesion.
This patient has a history of having five different episodes of basal cell carcinoma starting at the age of 27, and had one malignant melanoma at age 35. He is now 46, and has suffered from numerous severe sunburns which caused blistering and peeling. This patient was diagnosed with dysplastic nevus syndrome (over 100 atypical moles) and has been told that he is certain to have additional melanomas at some point in the future. Doctors have already confirmed that he has had basal cell carcinoma on his right jaw line, which resulted to Mohs procedure that was performed in December of 2011.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments.
Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in.”